Cargando…
Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
BACKGROUND: Little is known about prognosis of metastatic patients after receiving a first-line treatment and failure. Our group already showed in pre-treated patients enrolled in phase I clinical trials that a performance status (PS) > 2 and an LDH > 600 UI/L were independent prognostic facto...
Autores principales: | Belbaraka, Rhizlane, Trédan, Olivier, Ray-Coquard, Isabelle, Chvetzoff, Giselle, Bajard, Agathe, Pérol, David, Ismaili, Nabil, Ismaili, Mohammed, Errihani, Hassan, Bachelot, Thomas, Rebattu, Paul |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904794/ https://www.ncbi.nlm.nih.gov/pubmed/20537187 http://dx.doi.org/10.1186/1756-0500-3-164 |
Ejemplares similares
-
Validation of prognostic scores for survival in cancer patients beyond first-line therapy
por: Trédan, Olivier, et al.
Publicado: (2011) -
Primary lymphoma of the prostate treated with rituximab-based chemotherapy: a case report and review of the literature
por: Taleb, Amina, et al.
Publicado: (2009) -
Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution
por: Ismaili, Nabil, et al.
Publicado: (2010) -
Outcome of recurrent and metastatic small cell carcinoma of the bladder
por: Ismaili, Nabil, et al.
Publicado: (2009) -
Management of stage one and two-E gastric large B-cell lymphoma: chemotherapy alone or surgery followed by chemotherapy?
por: Sbitti, Yassir, et al.
Publicado: (2010)